247 related articles for article (PubMed ID: 31046481)
1. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
Kolli SS; Kepley AL; Cline A; Feldman SR
Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
[TBL] [Abstract][Full Text] [Related]
2. Safety concerns with current treatments for psoriasis in the elderly.
Di Caprio R; Caiazzo G; Cacciapuoti S; Fabbrocini G; Scala E; Balato A
Expert Opin Drug Saf; 2020 Apr; 19(4):523-531. PubMed ID: 32056449
[No Abstract] [Full Text] [Related]
3. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.
Hsu SH; Tsai TF
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790
[No Abstract] [Full Text] [Related]
4. Update on TNF Inhibitors.
Kerdel FA
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S67-70. PubMed ID: 27526035
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
7. Elderly psoriatic patients under biological therapies: an Italian experience.
Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
[TBL] [Abstract][Full Text] [Related]
8. Biologics in pediatric psoriasis - efficacy and safety.
Dogra S; Mahajan R
Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
[TBL] [Abstract][Full Text] [Related]
9. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
11. Psoriatic alopecia-like paradoxical reaction to certolizumab pegol.
Aragón-Miguel R; Calleja-Algarra A; Vico-Alonso C; Sánchez-Velázquez A; Garrido MC; Ortiz-Romero PL; Rivera-Díaz R
Int J Dermatol; 2019 Jun; 58(6):e118-e120. PubMed ID: 30825196
[No Abstract] [Full Text] [Related]
12. An update on the safety of apremilast for the treatment of plaque psoriasis.
Shavit E; Shear NH
Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
[No Abstract] [Full Text] [Related]
13. Psoriasis and pregnancy in the biologic era, a feared scenario. What do we do now?
Tirelli LL; Luna PC; Cristina E; Larralde M
Dermatol Ther; 2019 Nov; 32(6):e13137. PubMed ID: 31639245
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
15. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
16. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
17. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
[No Abstract] [Full Text] [Related]
18. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
[No Abstract] [Full Text] [Related]
19. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
20. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]